Physician profile
Lael E Forbes
NPI 1003826066
$8,702.53
in general payments reported to CMS, 2019-2025
14 companies · $170 in 2025
The $170 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,502 · 2020: $136 · 2021: $399 · 2022: $467 · 2023: $4,927 · 2024: $102 · 2025: $170.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,940 · Food and Beverage: $1,509 · Honoraria: $750.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,940.00 |
| Food and Beverage | $1,509.15 |
| Honoraria | $750.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $4,075.21 | 2021-2023 | Signia |
| W. L. Gore & Associates, INC. | $1,773.00 | 2019-2023 | Seamguard, Gore Synecor Biomaterial |
| Intra-Sana Laboratories | $966.40 | 2022-2023 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Covidien LP | $738.12 | 2019 | |
| Novo Nordisk INC | $602.72 | 2019-2025 | Wegovy |
| Medical Device Business Services, INC. | $125.00 | 2019 | |
| Ethicon US, LLC | $111.00 | 2019 | |
| Abbvie INC. | $82.58 | 2023-2024 | |
| Sumitomo Pharma America, INC. | $78.34 | 2024 | Gemtesa |
| Endo Pharmaceuticals INC. | $58.84 | 2019-2021 | |
| Glaxosmithkline, LLC. | $28.32 | 2023 | Trelegy Ellipta |
| Becton, Dickinson and Company | $27.50 | 2023 | Phasix Mesh |
| Sunovion Pharmaceuticals INC. | $19.46 | 2022 | |
| Tela Bio, INC. | $16.04 | 2023 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lael Forbes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.